Hospira Inc completes acquisition Orchid’s API, R&D facilities

Hospira completes acquisition of Orchid’s API, R&D facilities

5:05 AM, 5th July 2014
Hospira Inc completes acquisition of Orchid’s API, R&D facilities

LAKE FOREST, US: Hospira Inc, the world’s leading provider of injectable drugs and infusion technologies, has completed the acquisition of an active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd, a leading Indian pharmaceuticals company, for approximately $218 million, after settling prior advances of approximately $30 million.

The acquisition enables Hospira, already a leader in certain critical antibiotic injectable products, to vertically integrate into the beta-lactam antibiotic APIs (penems and penicillins), and is also expected to improve Hospira’s cost position in this therapeutic space. In addition, backward integration into these beta-lactam APIs will improve the company’s security of supply. Beta-lactam antibiotics represent a class of drugs with a wide spectrum of antibacterial activity.

The API manufacturing facility - which is located in Aurangabad, India - has capabilities for manufacturing sterile APIs and employs approximately 665 employees including chemists, engineers and technicians. Hospira’s purchase also includes an associated Orchid R&D facility based in Chennai, India, that will be directed primarily to beta-lactam and other API development with approximately 110 scientific personnel.

“Hospira’s acquisition of the Orchid API facility will support supply continuity of key beta-lactam antibiotic products, improve our cost position and pave the way for future API development. We’re committed to the antibiotics space, and with our new colleagues from Orchid, we will continue to bring high-quality, lower-cost products to patients around the world,” said Dr C.Bhaktavatsala Rao, President and Managing Director, Hospira India.

© Worldofchemicals News

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Oxea declares force majeure for intermediates at Bay City facility, US

DALLAS, US: Oxea Corporation has encountered a significant production issue at its Bay City, Texas facility, US. Due to a malfunction in the productio ...

Read more
Sasol, Eni to conduct pre-feasibility study for GTL plant in Mozambique

JOHANNESBURG, SOUTH AFRICA: Sasol Limited (Sasol) announced a joint pre-feasibility study for a large-scale gas-to-liquids (GTL) plant, which will be ...

Read more
DIC to build polyphenylene sulfide compounds plant in China

TOKYO, JAPAN: DIC Corporation has resolved to build its first polyphenylene sulfide (PPS) compounds plant in the People’s Republic of China (PRC ...

Read more
PPG acquires Homax from Olympus Partners

PITTSBURGH, US: PPG Industries announced that its North American architectural coatings business has completed its acquisition of The Homax Group Inc, ...

Read more
Foster Wheeler bags Owens’ manufacturing facility contract in North Carolina, US

ZUG, SWITZERLAND: Foster Wheeler AG’s subsidiary of Global Engineering and Construction Group has been awarded an engineering, procurement and c ...

Read more
CB&I awarded LSB’s ammonia storage tank contract in Arkansas, US

THE WOODLANDS, US: CB&I has been awarded a contract by El Dorado Ammonia LLC, subsidiary of LSB Industries Inc. CB&I will provide engineering, ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X